Insert company logo

Decisive Coronary Care

Recognized in ACC/AHA Chest Pain Guidelines to help guide treatment for patients with suspected coronary artery disease (CAD), the CCTA + FFR_{CT} pathway combines anatomy and lesion-specific physiology, **offering clinicians a powerful tool in identifying clinically significant disease that was previously only available invasively**.

How it works

Order CCTA + Conditional FFR_{CT} Analysis

CCTA performed and images sent to Heartflow

Cloud-based FFR_{CT} Analysis delivered

Medical management personalized for optimal outcomes

A Proven Solution – See the Heartflow Difference

Increase your diagnostic confidence

$CCTA+FFR_{CT}$ delivers better diagnostic performance than other non-invasive cardiac tests and leads to better clinical decision making and improved patient outcomes.[1,2]

Help every patient own their heart health

$CCTA+FFR_{CT}$ enables physicians to provide patients with a visual understanding of their disease and impact it has on their heart.

Optimize patient care

$CCTA+FFR_{CT}$ enables physicians to confidently identify patients who can be treated with optimal medical therapy alone.[4]

See what might be missed

$CCTA+FFR_{CT}$ identifies disease other non-invasive cardiac tests may overlook.[2,3]

Patients can now be referred to [Insert Hospital Name]
to receive precise heart care using this proven, revolutionary technology.

Contact us for more information
XXX.XXX.XXXX

1. Douglas PS, et al. JAMA Cardiol. 2023. (PRECISE) doi:10.1001/jamacardio.2023.2595. **2.** Driessen, et al. J Am Coll Cardiol 2019. Norgaard, et al, Euro J Radiol 2015. **3.** Melikian, et al. JACC: Cardiovasc Interv 2010. Jung, et al. Euro Heart J 2008. Koo, et al. J Am Coll Cardiol 2011. Min, et al. JAMA 2012. Nørgaard, et al. J Am Coll Cardiol 2014. **4.** Patel, et al. J Am Coll Cardiol 2019.

Heartflow, Inc. | 331 E. Evelyn Avenue | Mountain View, CA 94041 | ph: +1 650.241.1221 | info@Heartflow.com | Heartflow.com

DOC-125682212 V4